Navigation Links
Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Date:4/20/2012

SAN FRANCISCO, April 20, 2012 /PRNewswire/ -- Health insurers should use both medical and pharmacy data to forecast specialty medication utilization and improve outcomes for members, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care Pharmacy (AMCP)'s 24th Annual Meeting & Expo in San Francisco.

Pharmacy benefit managers (PBMs) have experienced a rapid rise in expensive specialty prescription drug use within the past few years. In 2011, specialty drugs comprised 0.5 percent of all claims but 15.2 percent of all prescription benefit expenditures across Prime's member network. In addition, the average specialty per-prescription cost was $2,637 in 2010 and total paid per capita increased 12.9 percent from 2010 ($10.24 to $11.36 per member per month). Previous studies have estimated that specialty medication drug spend could increase from 20 percent to 50 percent by 2030, highlighting the need for health insurers to better understand how to trend and forecast these costs due to rapid growth rate.

"Specialty drugs offer life-saving treatment for patients with chronic illnesses, but they also carry a huge price tag, continuing to rise by double digits each year," said Patrick Gleason, PharmD, director of clinical outcomes assessment at Prime. "Health insurers and plan sponsors need to be able to forecast these costs and also ensure the best outcomes for their members. For example, it's critical that insurers understand that of the 81.9 percent of members with Hepatitis C identified as untreated many are likely to receive care in the near future because new drugs have recently become available."

According to Prime's analysis, it may be easy to identify prevalence and treatment rates via International Classification of Disease, Ninth Revision (ICD9), procedure code and pharmacy claims for some diseases. However, more sophisticated algorithms may be nee
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  IQPC,s 19 th Software ... the chairman of the Summit Mr. Phani Bidarahalli , ... be joined by the expert speaker faculty including senior executive ... 11 – 12, at The Hotel Kabuki in ... available for download on the event website, which can be ...
(Date:5/5/2015)... , May 5, 2015 Big Market Research ... US, Europe , ( France , ... Spain , UK) and Japan . ... reviewed. The report provides the 5-year test volume and sales forecasts ... NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ...
(Date:5/5/2015)... Faced with fast economy and population growth, an ... China,s medical device industry has been growing rapidly ... have been Beijing , Shanghai ... cities. However, the entry of a large number of medical ... in first-tier cities increasingly saturated. How do medical device enterprises ...
Breaking Medicine Technology:Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4
... 19, 2007 - Amgen,(NASDAQ: AMGN) today ... study", a,randomized, double-blind, placebo-controlled, multicenter Phase ... 600 previously untreated,patients with extensive-stage small-cell ... study demonstrated,no statistically significant difference in ...
... Biomolecular Sciences Conference, THE WOODLANDS, Texas, April ... that data was presented,today highlighting potential therapeutic ... at the Society for Biomolecular,Sciences 13th Annual ... discoveries were made in a collaboration,between Lexicon ...
Cached Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5
(Date:5/5/2015)... 2015 " QuickPick Travel ” was featured ... takes a look small, medium, and large businesses making an ... and a business expert, conducted the business review and shared ... up to three weeks of vacation for free. , Vacations ... and explore the world. And when people are preparing for ...
(Date:5/5/2015)... 2015 This year, PolyU researchers garnered ... Merit Awards, three Gold Medals and four Silver Medals ... as follows: , (1) Grand Prize and Gold Medal ... Fashion Design and Fitting, Principal Investigator: Dr Allan Chee-kooi ... industry relies very much on the “mannequin” for many ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 The brains ... accelerated aging that correlate with slower information processing, according ... Graduate School of Public Health . , The ... with type 1 diabetes for cognitive difficulties. If progressive, ... diabetes. The study, funded by the National Institutes ...
(Date:5/5/2015)... 05, 2015 Rare Genomics Institute ... new study aimed at determining how crowdfunding can promote ... an international non-profit providing rare disease patients with access ... to scientists and researchers, and help for payment of ... am excited to see how crowdfunding will not only ...
Breaking Medicine News(10 mins):Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 3Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 4Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2
... offers 50 percent smaller size, 20 percent less ... in portable equipment, DALLAS, March 24 ... market, Texas Instruments (TI) (NYSE: TXN ),today ... ends (AFEs) for,portable to high-end ultrasound diagnostic equipment. ...
... Medicare & Medicaid Services Accepts as Complete DNV,s ... Application for Hospital Deeming Authority, HOUSTON, March ... has informed DNV Healthcare that its application to,deem hospitals in ... complete and ready for formal review., If approved, DNV ...
... and vision care with ... medical coverage, DETROIT, March ... all rolled into one product package., The "package" is Community Blue ... that will launch April 1. Community,Blue Plus combines preventive dental and vision ...
... Health care facilities, like all,Pennsylvania businesses, strive ... reducing workers, compensation expenses driven by claims made,against ... challenges,in the frequency and types of on the ... based law firm of Fried, Kane, Walters, Zuschlag,and ...
... and dementia patients and ... families regain what was once ... million Americans,including 250,000 Ohioans, struggle with the devastating effects ... the greater,Cleveland area offers new hope to Alzheimer,s patients ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... Ms. Nan Wang, Vice President, Ms. Helen Yang,International Business ... at the Brean Murray, Carret & Co. Fourth Investor ... p.m. China Standard Time at the,Grand Hyatt Hotel in ...
Cached Medicine News:Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 2Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 3Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 4Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Blue Cross Blue Shield of Michigan Pioneers 'Total Body' PPO Product 2Health News:Reducing Cost of Health Care by Addressing Workers' Compensation Costs 2Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China 2
... The Super 66® Stereo Fundus ... magnification viewing of the central retina. Its ... subtle macular and optic disc detail, making ... choroidal neovascular membranes, macular edema, serous detachments ...
... The original Volk 90D lens started the ... small 26mm diameter ring design which is ... Aspheric optical design expands the usable viewing ... Volk 90D has good small pupil capabilities, ...
The Volk 60D provides high magnification - making it ideal for detailed disc and macular viewing. Its 31mm diameter facilitates easy handling within the orbital area. Available with SupraCoat (argon...
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
Medicine Products: